Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity by Hyejin Jeon et al.
RESEARCH Open Access
Plasminogen activator inhibitor type 1 regulates
microglial motility and phagocytic activity
Hyejin Jeon1, Jong-Heon Kim1, Jae-Hong Kim1, Won-Ha Lee2, Myung-Shik Lee3 and Kyoungho Suk1*
Abstract
Background: Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of urokinase type plasminogen
activators (uPA) and tissue type plasminogen activators (tPA), which mediate fibrinolysis. PAI-1 is also involved in
the innate immunity by regulating cell migration and phagocytosis. However, little is known about the role of PAI-1
in the central nervous system.
Methods: In this study, we identified PAI-1 in the culture medium of mouse mixed glial cells by liquid
chromatography and tandem mass spectrometry. Secretion of PAI-1 from glial cultures was detected by ELISA and
western blotting analysis. Cell migration was evaluated by in vitro scratch-wound healing assay or Boyden chamber
assay and an in vivo stab wound injury model. Phagocytic activity was measured by uptake of zymosan particles.
Results: The levels of PAI-1 mRNA and protein expression were increased by lipopolysaccharide and interferon-γ
stimulation in both microglia and astrocytes. PAI-1 promoted the migration of microglial cells in culture via the
low-density lipoprotein receptor-related protein (LRP) 1/Janus kinase (JAK)/signal transducer and activator of
transcription (STAT)1 axis. PAI-1 also increased microglial migration in vivo when injected into mouse brain. PAI-1-
mediated microglial migration was independent of protease inhibition, because an R346A mutant of PAI-1 with
impaired PA inhibitory activity also promoted microglial migration. Moreover, PAI-1 was able to modulate microglial
phagocytic activity. PAI-1 inhibited microglial engulfment of zymosan particles in a vitronectin- and Toll-like
receptor 2/6-dependent manner.
Conclusion: Our results indicate that glia-derived PAI-1 may regulate microglial migration and phagocytosis in an
autocrine or paracrine manner. This may have important implications in the regulation of brain microglial activities
in health and disease.
Introduction
Activated glial cells secrete a variety of proteins includ-
ing proinflammatory cytokines, chemokines, and neuro-
toxic factors under inflammatory or pathological
conditions [1,2]. Secretomic analysis has been previously
conducted for astrocytes [3-5] and microglia [6,7] to de-
termine the profile of the secreted proteins. Some of
these secreted proteins play important roles in the pro-
gression of inflammatory diseases in the brain, and serve
as biomarkers that can be used to guide diagnosis and
drug therapy. Microglia, the resident macrophages of the
CNS, constitute the brain’s innate immune system and
play a pivotal role in neuroinflammation and host
defense against microbial agents [8-12]. Microglia, as
phagocytes, engulf invaded pathogens, apoptotic cells,
and their debris [11,13]. Chronically activated microglia
also contribute to neurotoxicity in neurodegenerative
diseases, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis, Huntington’s
disease, and multiple sclerosis (MS) [14-19]. Migration
of microglia, via extension of their processes, to the site
of inflammation is a key step in the progression of the
inflammatory brain diseases [20].
Plasminogen activator inhibitor type 1 (PAI-1), also
known as serine protease inhibitor E1, is expressed in
various cell types such as adipocytes, glomerular mesan-
gial cells, epithelial cells, vascular endothelial cells, vas-
cular smooth-muscle cells, monocytes/macrophages, and
astrocytes [21-23]. PAI-1 acts as the main inhibitor of
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both urokinase type plasminogen activators (uPA) and
tissue type plasminogen activators (tPA), which convert
plasminogen to plasmin. This plasmin activator/inhibitor
system is involved in the regulation of fibrinolysis, and
remodeling of the extracellular matrix, cell migration,
and invasion of tumor cells [21,24-26]. PAI-1 is also
involved in the distinction between viable and apoptotic
cells, and PAI-1 regulates the phagocytosis of apoptotic
cells [27]. PAI-1 plays a dual role in the regulation of cell
migration through differential interactions with its bind-
ing partners such as uPA, tPA, vitronectin, and low-
density lipoprotein receptor-related protein (LRP)1. The
PAI–vitronectin complex binds to the Arg-Gly-Asp
motif of αv integrins and inhibits the integrin-mediated
cell migration [28-33]. The PAI-1/uPA/uPAR complex
inhibits uPA-induced cell migration [34], whereas the
interaction between PAI-1 and LRP1 stimulates the
movement of monocytes [35-37]. The LRP1/tPA/PAI-1
complex induces Mac-1-dependent macrophage migra-
tion [37]. Thus, the effect of PAI-1 on cell migration
depends on the binding proteins involved, which are
expressed in a cell- and tissue-specific manner. Overex-
pression of PAI-1 has been detected in various brain dis-
orders, such as glioma, ischemic stroke, MS, and AD
[18,38-42]. Several reports have indicated an important
role of PAI-1 in the CNS injury and pathology. Increased
PAI-1 was shown to interfere with the clearance and
degradation of amyloid-β by blocking tPA, and inactiva-
tion of PAI-1 retarded the progression of AD pathology
[39]. PAI-1 reduced brain edema and axonal degener-
ation after ischemic brain injury [42]. PAI-1 produced by
astrocytes protected neurons against N-methyl-D-aspar-
tate receptor-mediated excitotoxicity [43], and PAI-1
expressed in olfactory ensheathing glia was shown to
promote axonal regeneration [44]. However, the role of
PAI-1 in the regulation of microglial functions has not
been investigated.
In the present study, we identified PAI-1 as a protein
secreted from mixed glial cultures after stimulation with
lipopolysaccharide (LPS) and interferon (IFN)-γ. PAI-1
levels were increased in both microglia and astrocytes by
inflammatory stimulation. Subsequent studies showed
that glia-derived PAI-1 specifically regulated microglial
cell motility. Using LRP1 small interfering (si)RNA and
low-density lipoprotein receptor-associated protein
(RAP), we found that PAI-1 promoted microglial migra-
tion through an LRP1-dependent mechanism. Further
examination of the signaling pathways indicated that the
PAI-1/LRP1 complex enhanced microglial migration via
the JAK/STAT1 pathway. The migration-promoting ef-
fect of PAI-1 did not require the PA inhibitory activity,
either in vitro or in vivo. In addition, we found that PAI-
1 inhibits microglial phagocytic activity. Studies using
PAI-1 mutant proteins indicated that the inhibitory effect
of PAI-1 on microglial phagocytosis was dependent on
vitronectin but not LRP1. Taken together, our results sug-
gest that PAI-1 may be released predominantly by micro-
glia and astrocytes under inflammatory conditions of the
brain, and the secreted PAI-1 protein may regulate micro-
glial migration and phagocytosis in CNS inflammation.
Methods
The animals used in this study were maintained under
temperature- and humidity-controlled conditions with a
12 hour light/12 hour dark cycle. All animal experiments
were approved by the institutional review board of
Kyungpook National University School of Medicine and
were carried out in accordance with the guidelines in
the NIH Guide for the Care and Use of Laboratory
Animals.
Reagents
LPS (from Escherichia coli 0111: B4 prepared by phen-
olic extraction and gel filtration chromatography), BSA,
and rabbit serum were all purchased from Sigma (Sigma,
St Louis, MN, USA). Recombinant mouse IFN-γ, RAP
protein, and recombinant human vitronectin protein
were purchased from R&D Systems (Minneapolis, MN,
USA). Lipoteichoic acid (LTA) from Bacillus subtilis was
purchased from InvivoGen (Carlsbad, CA, USA). 5-
chloromethyl-fluoresceindiacetate (CMFDA) was pur-
chased from Molecular Probes Inc (Eugene, OR, USA).
JAK inhibitor AG490 ((E)-N-benzyl-2-cyano-3-(3,4-dihy-
droxyphenyl) acrylamide a-cyano-(3,4-dihydroxy)-N-ben-
zylcinnamide tyrphostin B42), was purchased from
Calbiochem (La Jolla, CA, USA). Recombinant mouse
PAI-1 protein was purchased from American Diagnostica
(Greenwich, CT, USA), and was diluted in PBS. All other
chemicals, unless otherwise stated, were obtained from
Sigma.
Preparation of recombinant human PAI-1 proteins
The bacterially expressed recombinant human PAI-1
wild-type and mutant proteins (Q123K and R346A) were
prepared as previously described [45]. The PAI-1 mutant
Q123K was unable to bind to vitronectin [16,46,47], and
the R346A mutant was unable to inhibit PA [28,45]. In
brief, the coding region of recombinant wild-type human
PAI-1 (amino acids 24–402, Swiss-Prot primary acces-
sion number P22777) was cloned into the pRSET B vec-
tor with an N-terminal polyhistidine (6 ×His) tag (kindly
provided by Dr Hana Im, Sejong University, Seoul,
Korea) [47]. This PAI-1 construct lacks the N-terminal
secretory signal region. Human PAI-1 mutants were
generated by using a site-directed mutagenesis kit (Quik-
Change; Stratagene, La Jolla, CA, USA) in accordance
with the manufacturer’s instructions. The pRSET B vec-
tor containing the wild-type or mutant PAI-1 cDNA was
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transformed into the competent E. coli strain BL21(DE3)
pLysS, which was then grown at 37°C in 500 ml of Luria
broth medium supplemented with 100 μg/ml ampicillin.
The expression of recombinant proteins was induced with
0.1 mmol/l Isopropyl β-D-1-thiogalactopyranoside (IPTG)
for 3 hours, and then cells were lysed by sonication. The
protein was purified by using nickel-nitrilotriacetic acid
(Ni-NTA) beads (Qiagen, Chatsworth, CA, USA) in accord-
ance with the manufacturer’s instructions. Ni-NTA-bound
proteins were then eluted with an buffer containing
50 mmol/l Tris–HCl (pH 8.0), 100 mmol/l NaCl, and
200 mmol/l imidazole. The purified protein was dialyzed
(Slide-A-Lyzer Dialysis Cassettes; Pierce, Rockford, IL,
USA), and then concentrated using centrifugal dialysis fil-
tration tubes (Millipore, Billerica, MA, USA).
Cell cultures
The BV-2 mouse microglial cell line, which exhibits
phenotypic and functional properties comparable with
those of primary microglial cells [48,49], was grown and
maintained in DMEM containing 5% FBS, 2 mmol/l glu-
tamine, penicillin, and streptomycin (Gibco, Gaithers-
burg, MD, USA) at 37°C in 95% air/5% CO2. C6 rat
glioma cells were grown and maintained under the same
condition as the BV-2 microglial cells. Primary mixed
glial cells and astrocyte cultures were prepared as previ-
ously described [50]. In brief, the forebrains of newborn
ICR mice were chopped and dissociated by mechanical
disruption using a nylon mesh.
The cells were seeded into culture flasks. Mixed glial
cultures were established after in vitro culture for 10 to
14 days at 37°C in 95% air/5% CO2. Mixed glial cultures
were composed of 61.86 ± 1.44% astrocytes, 28.73± 2.23%
microglia, and 9.36± 1.92% ‘other cell types’ as determined
by glial fibrillary acidic protein (GFAP) and ionized cal-
cium binding adaptor molecule 1 (Iba-1) staining [51].
Astrocytes were isolated from mixed glial cultures by
shaking at 270 rpm for 2 hours. This resulted in the de-
tachment of microglia, whereas astrocytes remained
attached to the bottom of the culture flask. The detached
microglia were aspirated, and the remaining astrocytes
were used for experiments. Astrocyte cultures were com-
posed of 92.56 ± 3.14% astrocytes, 0.45± 1.0% microglia,
and 6.99± 2.23% other cell types as determined by GFAP
and Iba-1 staining.
Primary microglial cultures were separately prepared
by mild trypsinization as previously described [52] with
minor modifications. After in vitro culture for 10 to
14 days, microglial cells were isolated from mixed glial
cultures by mild trypsinization. Mixed glial cultures were
incubated with a trypsin solution (0.25% trypsin,
1 mmol/l EDTA in Hank’s balanced salt solution) diluted
1:4 in PBS containing 1 mmol/l CaCl2 for 30 to 60 min-
utes. This resulted in the detachment of the upper layer
of astrocytes in one piece, whereas microglia remained
attached to the bottom of the culture flask. The
detached layer of astrocytes was aspirated, and the
remaining microglia were used for experiments. The
purity of microglial cultures was greater than 95% as
determined by GFAP and Iba-1 staining. Primary glial
cultures were grown and maintained in DMEM supple-
mented with 10% FBS, 100 U/ml of penicillin, and
100 μg/ml of streptomycin.
Primary cultures of dissociated cerebral cortical neu-
rons were prepared as previously described [53]. Cortical
neurons were grown in neurobasal medium containing
10% FBS, 0.5 mmol/l glutamine, 100 U/ml of penicillin,
100 μg/ml of streptomycin, N2 supplement (Gibco), and
B27 supplement (Gibco). The purity of the neuronal cul-
tures was determined by immunocytochemical staining,
using an antibody against a neuron-specific marker,
microtubule-associated protein 2 (Promega, Madison,
WI, USA).
Proteomic analysis of conditioned medium of mixed glial
cultures
Conditioned medium from mixed glial cultures or cell
extracts was prepared as previously described [51]. Cells
were treated with a combination of LPS (100 ng/ml) and
IFN-γ (50 U/ml) at 37°C in 95% air/5% CO2 for 24
hours. The stimulation was performed under serum-free
conditions. Precipitated proteins were analyzed by liquid
chromatography and tandem mass spectrometry (LC-
MS/MS) as previously described [51,54].
Traditional reverse transcriptase PCR and real-time PCR
Total RNA was extracted from cells by using TRIzol re-
agent (Invitrogen), in accordance with the manufac-
turer’s protocol. Reverse transcription was conducted
using reverse transcriptase (Superscript II; Invitrogen)
and oligo(dT) primers. PCR amplification, using specific
primer sets, was carried out at an annealing temperature
of 55 to 60°C for 25–30 cycles. The PCR was performed
in a thermal cycler (DNA Engine Tetrad Peltier; MJ Re-
search, Waltham, MA, USA). For the analysis of PCR
products, 10 μl of each PCR was separated by electro-
phoresis in 1% agarose gels and viewed under UV light.
β-actin was used as an internal control. Nucleotide
sequences of the primers were based on published
cDNA sequences of mouse LRP-1, PAI-1, Toll-like re-
ceptor (TLR)2, TLR6, dectin-1, and β-actin (Table 1)
Real-time PCR was performed using a commercial kit
(One Step SYBRWPrimeScriptTM; Takara Bio Inc, Japan)
in accordance with the manufacturer’s instructions, fol-
lowed by detection using the ABI PrismW 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA).
Nucleotide sequences of the primers were based on
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published cDNA sequences of mouse PAI-1 and mouse
GAPDH (Table 1), the latter used as an internal control.
Western blotting analysis
Western blotting analysis was carried out as previously
described [51]. In brief, cells were treated with LPS
(100 ng/ml), IFN-γ (50 U/ml), or mouse PAI-1 (100 ng/ml)
at 37°C in 95% air/5% CO2. Cells were washed with PBS
and lysed in triple-detergent lysis buffer (50 mmol/l Tris–
HCl (pH 8.0), 150 mmol/l NaCl, 0.02% sodium azide, and
1% NP-40). After SDS-PAGE separation of the cell lysates,
proteins were transferred to nitrocellulose membranes
(Amersham Biosciences, Piscataway, NJ, USA). The mem-
branes were blocked with 5% skim milk, and sequentially
incubated with primary antibodies (rabbit polyclonal anti-
mouse PAI-1 antibody, anti-LRP1 antibody (H-80; raised
against the N-terminal extracellular domain of 515 kDa
LRP1) (both Santa Cruz Biotechnology, Santa Cruz, CA,
USA), rabbit polyclonal anti-STAT1 antibody, rabbit poly-
clonal anti-phospho-STAT1 antibody (both Cell Signaling
Technology, Beverly, MA, USA), monoclonal anti-mouse
TLR2 antibody, monoclonal anti-mouse TLR6 antibody
monoclonal anti-mouse TLR9 antibody (all Imgenex, San
Diego, CA, USA), or monoclonal anti-α-tubulin clone B-5-
1-2 mouse ascites fluid (Sigma)), and horseradish peroxid-
ase (HRP)-conjugated secondary antibodies (anti-mouse
IgG (Amersham Biosciences) and anti-rabbit IgG (Cell
Signaling Technology)), followed by ECL detection (Amer-
sham Biosciences).
Indirect ELISA for plasminogen activator inhibitor type 1
Indirect ELISA was used for the recombinant mouse
PAI-1 protein measurements. Cells were treated with a
combination of LPS (100 ng/ml) and IFN-γ (50 U/ml)
for 24 hours. The stimulation was performed under
serum-free conditions. The conditioned medium was
then collected, and separated by centrifugation at 400 g
for 5 minutes to remove cell debris. The wells of micro-
titer plates were coated with conditioned medium over-
night (diluted 1:1 in 50 mmol/l carbonate buffer, pH 9.6;
100 μl/well in triplicate wells). Plates were washed with
PBS plus 0.1% Triton X-100 and blocked with PBS plus
5% BSA for 1 hour. Plates were emptied, and any
remaining liquid was tapped out onto dry paper towels.
Rabbit polyclonal anti-mouse PAI-1 antibody was added
(1 μg/ml; 100 μl per well) and incubated for 5 hours.
Plates were washed three times with PBS-T to remove
unbound antibody. Horseradish peroxidase-labeled anti-
rabbit IgG was added (1:1000 dilution; 100 μl per well)
and incubated for 1 hour. Plates were washed three
times with PBS-T and developed by the addition of
100 μl of tetramethylbenzidene peroxide-based substrate
solution (R&D Systems). The recombinant mouse PAI-1
protein was used as a standard.
Nitrite quantification
Cells were seeded at the density of 5 × 104 cells/well in 96-
well plates, and treated with various stimuli for 24 hours in
serum-free medium. Production of NO was estimated by
measuring the amount of nitrite, a stable metabolite of NO,
using Griess reagent, as previously described [51].
Assessment of cell viability and proliferation
Cells (5 × 104 cells in 100 μl/well for cell viability assay;
5 × 103 cells in 100 μl/well for cell proliferation assay)
were seeded in 96-well plates and treated with various
stimuli for the specific time periods in the serum-free
medium. After treatment, 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) assay was per-
formed as previously described [51].
Microglia/neuron co-culture
For the co-culture of microglia and neurons, primary
microglia were seeded at a density of 4 × 104 cells/well
in 96-well plates at 37°C in 95% air/5% CO2. After 16
hours of incubation, the cells were treated with LPS
(100 ng/ml) and mouse PAI-1 protein (100 ng/ml) for
12 hours. Culture medium was then removed, and cells
were washed with PBS. CMFDA-labeled mouse primary
cortical neurons (4 × 104 cells/well) were added to
microglia-plated wells and incubated in neurobasal
Table 1 List of PCR primers used in the study
Name Accession number Forward primer (5′!3′)
Reverse transcriptase PCR
LRP1 NM_008512 Forward GCGTGGGTGTGTGATGGCGA
Reverse GTTGCGCAGGCCAGGCACTA
PAI-1 NM_008871 Forward GTCTTTCCGACCAAGAGCAG
Reverse GCCGAACCACAAAGAGAAAG
TLR2 NM_011905.3 Forward ACAGCTACCTGTGTGACTCTCCGCC
Reverse GGTCTTGGTGTTCATTATCTTGCGC
TLR6 NM_011604.3 Forward CTGCCCTGGTATGTGAGGAT
Reverse TCTGGATGAAGTGGGGAGAC
Dectin-1 AY534909.1 Forward GACTTCAGCACTCAAGACATCC
Reverse TTGTGTCGCCAAAATGCTAGG
β-actin NM_007393.3 Forward ATCCGTAAAGACCTCTATGC
Reverse AACGCAGCTCAGTAACAGTC
Real-time PCR
PAI-1 NM_008871 Forward CATGCCCCACTTCTTCAAGCT
Reverse TGGTATGCCTTTCCACCCAGT
GAPDH NM_008084.2 Forward TGGGCTACACTGAGCACCAG
Reverse GGGTGTCGCTGTTGAAGTCA
LRP, Low-density lipoprotein receptor-related protein; PAI, plasminogen
activator inhibitor; TLR, Toll-like receptor.
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medium containing 10% FBS. After an additional 24
hours incubation period, the number of CMFDA-labeled
cells was counted at ×100 magnification in four visual
fields in each well using a fluorescence microscope
(CK2; Olympus, Tokyo, Japan). Images of five random
fields per well were captured and analyzed by an imaging
system (MetaMorph; Universal Imaging Corp, West
Chester, PA) [53].
Cell migration assays in vitro
Cell migration was determined by using an in vitro
scratch-wound healing assay or Boyden chamber assay.
The scratch-wound healing assay was performed as pre-
viously described [55,56]. In brief, BV-2 mouse micro-
glial cells and C6 rat glioma cells were seeded at a
density of 8 × 104 cells/well in 96-well plates, and incu-
bated at 37°C under in 95% air/ CO2 for 14 hours. A
scratch wound was created with a 200 μl pipette tip on
the confluent cell monolayer. Cells were treated with or
without pharmacological inhibitors, PAI-1 protein, BSA,
RAP protein, astrocyte-conditioned medium (ACM),
anti-PAI-1 antibody, or rabbit serum. Cells were allowed
to recover for 24 hours in serum-free medium. The
wound closure was then viewed under a microscope
(Olympus CK2; original magnification, × 150). Relative cell
migration distance was determined by measuring the
wound width and subtracting this from the initial value:
fold increase of migration distance = (sample initial
wound width at time 0 minus sample wound width at 24
hours of measurement)/(control initial wound width at
time 0 minus control wound width at 24 hours of
measurement).
A total of three areas were selected and examined in
each well. The fold increase of migration distance was
based on the average wound width in three areas (an
area with maximum width, an area with minimum
width, and a randomly chosen area). The results were
presented as the fold increase of the migration distance
compared with control.
A 48-well Boyden chamber (NeuroProbe, Gaithers-
burg, MD, USA) was also used for the measurement of
cell migration, in accordance with the manufacturer’s
instructions. The recombinant mouse PAI-1 protein in
DMEM containing 10% FBS was placed into the lower
wells, which were separated from the upper wells by
polyvinylpyrrolidone-free polycarbonate filters (8 μm
pore size, 25 × 80 mm; NeuroProbe). Primary microglial
cells were harvested by trypsinization, resuspended in
serum-free DMEM, and added to the upper chamber at
a density of 5 × 104 cells/well. Cells were incubated at
37°C under in 95% air/5% CO2 for 24 hours. At the end
of the incubation, any non-migrating cells on the upper
side of the membrane were removed with a cotton swab.
Migrated cells on the lower part of the membrane were
fixed in methanol for 10 minutes and stained with
Mayer’s hematoxylin (Dako Cytomation, Glostrup, Den-
mark) for 20 minutes. Photomicrographs of five ran-
domly chosen fields were taken (Olympus CK2) (original
magnification, × 100), and cells were enumerated to cal-
culate the average number of cells that had migrated. All
migrated cells were counted (MetaMorph imaging sys-
tem; Molecular Devices). Results are presented as the
mean ± SD of triplicates.
Small interfering RNA transfection




AUACAUCUUGUAGGUAGtt)were purchased from Santa
Cruz Biotechnology. siRNA transfection of BV-2 micro-
glial cells was performed (LipofectamineTM 2000; Invitro-
gen) in accordance with the manufacturer’s instructions.
The cells were harvested 48 hours after transfection, and
used for the experiments.
Dot blotting analysis
Cells were treated with LPS (100 ng/ml), IFN-γ (50 U/
ml), or mouse PAI-1 protein (100 ng/ml). Cells were
then washed with PBS and lysed in triple-detergent lysis
buffer (50 mmol/l Tris–HCl (pH 8.0), 150 mmol/l NaCl,
0.02% sodium azide, 1% NP-40). Cell lysates were spot-
ted slowly onto nitrocellulose membranes (Hybond ECL;
Amersham Biosciences). The membranes were then
blocked with 5% skim milk and sequentially incubated
with anti-LRP1 antibody and HRP-conjugated anti-
rabbit IgG followed by ECL detection.
Astrocyte-conditioned medium
To prepare ACM, primary astrocyte cultures were
seeded at the density of 1.5 × 106 cells in 100 mm cul-
ture dishes. Primary astrocyte cultures were treated with
a combination of LPS (100 ng/ml) and IFN-γ (50 U/ml)
for 12 hours. Cells were then washed twice with PBS,
and cultured in fresh DMEM for an additional 24 hours.
The ACM was then collected, separated by centrifuga-
tion at 400 g for 5 minutes to remove cell debris, and
stored at −80°C until further analysis.
Intrastriatal injection of human plasminogen activator
inhibitor type 1 (PAI-1) protein
Mice (body weight 30 g) were anesthetized by intraperi-
toneal injection of tiletamine/zolazepam (30 mg/kg
(Zoletil; Virbac Laboratories, Carros, France)) and xyla-
zine (10 mg/kg (Ropum; Bayer, Puteaux, France)), and
positioned in a stereotaxic apparatus (Stoelting, Wood
Dale, IL, USA). The mice were placed on a homeothermic
heat blanket (Harvard Apparatus Co., South Natick, MA,
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USA) at 37°C to maintain normal body temperature dur-
ing surgery. The skull was exposed by a skin incision, and
a small hole was drilled through the skull. To avoid pas-
sing through the ventricles, the guide cannula was
implanted at the stereotaxic coordinates of 1 mm anterior
to the bregma, 2 mm lateral to the bregma, and 4 mm
below the skull using a 22 G needle, and cemented. Intras-
triatal injection of the vehicle (dialyzed elution buffer) or
recombinant human PAI-1 protein of wild-type or R346A
mutant (1 μl; 1.5 μg/μl) was performed using a 26 G nee-
dle. Denatured PAI-I protein, which was used as a control,
was prepared by heating for 15 minutes at 95°C. The flow
rate of the injection was 0.1 μl/min maintained by a
microsyringe pump (Harvard Apparatus Co.). After re-
moving the needle, the skin was sutured with 6.0 mm silk
thread. The mice were killed 48 hours after the injection.
Immunohistochemistry
Mice were anesthetized with ether, and transcardially
perfused with 4% paraformaldehyde in PBS. Brains were
post-fixed and cryoprotected with 30% sucrose solution
for 24 hours. The fixed brains were embedded in opti-
mal cutting temperature compound (Tissue-Tek; Sakura
Fine-Tek, Tokyo Japan) and then cut into 12 μm-thick
coronal sections on a cryostat. The tissues were permea-
bilized in 0.1% Triton X-100, and blocked with 1% BSA
and 5% normal serum. After washing with PBS, the sec-
tions were incubated at 4°C overnight with rabbit poly-
clonal Iba-1 antibody (1:500 dilution; Wako, Tokyo,
Japan). The sections were then incubated with biotiny-
lated anti-rabbit IgG antibody (1:200 dilution; Vector
Laboratories, Burlingame, CA, USA). Subsequently,
the sections were incubated with avidin–biotin com-
plex reagents (Vector Laboratories) for 30 minutes
at room temperature, followed by detection with
diaminobenzidine.
Stab-injury and cell-injection assay
To evaluate in vivo microglial cell migration, we used
a stab-wound injury model as described previously
[57,58]. ICR mice (30 g) were anesthetized by intra-
peritoneal injection of tiletamine/zolazepam 30 mg/kg
and xylazine 10 mg/kg, and positioned in a stereo-
taxic apparatus, on a homeothermic heat blanket at
37°C to maintain normal body temperature during
surgery. The skull was exposed by a sagittal skin inci-
sion, and a small hole was drilled through the skull.
The guide cannula was implanted at 4 mm lateral
from the bregma, and 3 mm below the skull using a
22 G needle, and cemented. After 3 days, the skull
bone located at 2 mm posterior from the guide can-
nula was thinned with a high-speed drill, and then a
3 × 2.5 × 0.1 mm sterilized razor blade was stereotaxic-
ally inserted to a depth of 3 mm below the skull to create a
coronal stab injury, and immediately removed. After re-
moving the blade, the bone was covered (Bone Wax; Ethi-
con Inc, Somerville, NJ, USA). Primary microglial cells
(7.0 × 105 cells) were incubated with 1 μg/ml of recombin-
ant human PAI-1 proteins (denatured PAI-1 wild-type as a
control, wild-type PAI-1, and PAI-1 mutant R346A) in six-
well plates for 12 hours, and labeled with 5 μmol/l
CMFDA for 15 minutes. Intracortical cell injection (to-
gether with 1 μl PAI-1 proteins at 1 μg/μl) was performed
using a 26 G needle through a guide cannula with a flow
rate of 0.1 μl/min using a microsyringe pump. After sur-
gery, skin was sutured with 6.0 mm silk thread. At 72
hours after the injection, the mice were killed.
Migration of CMFDA-labeled microglial cells was esti-
mated using immunofluorescence assay. Iba-1 immuno-
fluorescence staining was performed as described above
for immunohistochemistry, except the secondary antibody
was donkey Cy3-conjugated anti-rabbit antibody (1:1000
dilution; Jackson Immunoresearch Laboratories, West
Grove, PA, USA). The sections were mounted on gelatin-
coated slides and allowed to air-dry overnight.
Data acquisition and immunohistological intensity
measurement
The level of coronal sections that passed the striatum was
determined in accordance with a mouse brain atlas. Tiled
images of each section were captured with a charge-
coupled device color video camera (D70; Olympus)
through a 100 × objective lens attached to a microscope
(BX51; Olympus). A composite of the images (640 × 480
pixels each; 1 pixel = 2.5× 2.5 μm) was then constructed
for each section with Photoshop CS3. Immunohistological
intensity analysis of Iba-1 staining was performed (Image J;
NIH, Bethesda, MD, USA) as previously described [59].
Composite images of stained sections were fast Fourier
transform band-pass filtered to eliminate low-frequency
drifts (>20 pixels = 50 μm) and high-frequency noises (<1
pixel = 2.5 μm). The image was set with a binary threshold
of 50% of the background level, and then the particles were
converted to a subthreshold image area with a size of 20
to 300 pixels, which was judged as showing the Iba-1-
positive cells. This range (20 to 300 pixels) was obtained
from the analyzed size of Iba-1-positive cells from six sec-
tions for each animal. To count the Iba-1 positive cells,
five squares (300×300 μm) were placed around the injec-
tion site in the subthreshold image of the six independent
sections, and the cells in the five squares were counted
and statistically analyzed.
Phagocytosis of fluorescent zymosan particles
BV-2 microglial cells were seeded at a density of
7.5 × 104 cells/well in 24-well plates. Cells were treated
with the recombinant human PAI-1 protein (100 ng/ml),
mouse PAI-1 protein (0.1 to 1 μg/ml), BSA (2.2 or
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22.0 nmol/l), monoclonal anti-mouse TLR2 antibody,
polyclonal anti-mouse integrin β3 (ITGB3) antibody
(Cell Signaling Technology), and vitronectin (1 μg/ml)
for 1 hour in serum-free DMEM. Cells were then incu-
bated at 37°C for 3 hours with 30 μg/ml of fluorescent
zymosan particles (zymosan A (Saccharomyces cerevi-
siae) BioParticles conjugated with Alexa Fluor 594; Mo-
lecular Probes Inc). Primary microglia cultures were
similarly treated with mouse PAI-1 (100 ng/ml) or RAP
(5 μg/ml) for 1 hour, and then incubated with 30 μg/ml
of zymosan particles for 90 minutes. Cells were then
washed five times with ice-cold PBS to remove bound
particles. Photomicrographs of five randomly chosen
fields were taken (CK2; Olympus) in three separate
experiments. A minimum of 400 microglial cells per well
were counted, and the percentage of phagocytic cells was
determined as previously described [51]. Recent reports
have indicated that washing three to five times with ice-cold
PBS effectively removed extracellular bacteria [60] and
zymosan particles [61,62]. We also determined by confocal
microscopy whether bound particles could be removed by
washing five times with ice-cold PBS. After phagocytosis
assay, microglial cells with different focal planes were exam-
ined under a confocal microscope to visualize the uptake of
fluorescent particles. The results indicated that repeated
washes could remove surface-bound particles efficiently
(data not shown).
Statistical analysis
All data are presented as mean ± SD from three or more
independent experiments, unless stated otherwise. Stat-
istical comparisons between different treatments were
performed by a Student’s t-test or one-way ANOVA with
Dunnett’s multiple comparisons by using SPSS software
(version 18.0; SPSS Inc, Chicago, IL). P< 0.05 was con-
sidered significant.
Results
Increase in plasminogen activator inhibitor type 1 (PAI-1)
level in both microglia and astrocytes by inflammatory
stimuli
Secreted proteins can regulate various cellular processes,
such as cell growth, proliferation, cell death/survival,
and homeostasis [63,64]. A large-scale analysis of glia-
derived proteins may broaden the understanding of glial
functions in the CNS [3,6,51]. We and others have previ-
ously investigated the secretome of brain glial cells
[3,4,6,7,51,65,66]. Proteins secreted from glial cells have
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Figure 1 Expression of plasminogen activator inhibitor type 1 (PAI-1) mRNA and protein in mixed glial cultures. (A) Cell lysates or
conditioned medium were prepared from either untreated or lipopolysaccharide (LPS)/interferon (IFN)-γ-treated mixed glial cultures (24 hours
treatment). Western blotting analysis was conducted to evaluate the expression level of the 47 kDa PAI-1 protein. Ponceau S staining images are
shown for comparison. (B) The mixed glial cells, microglia, and astrocytes were stimulated with a combination of LPS (100 ng/ml) and IFN-γ (50
U/ml) for 24 hours, and conditioned medium were collected. PA1-1 secretion was measured by ELISA. Results are given as mean ± SD (n= 3).
*P< 0.05, ** P< 0.01. (C, D) Real-time PCR was performed to detect PAI-1 mRNA expression in glial cells treated for 6 hours with LPS (100 ng/ml)
and IFN-γ (50 U/ml) either alone or in combination as indicated. GAPDH was used as an internal control. Results are given as mean ± SD (n= 3).
*P< 0.05, ** P< 0.01, NS = not significant; compared with the untreated control cells.
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been shown to regulate neuron–glia communication and
to play important roles in interglial interactions [67]. In
the present study, we identified PAI-1 as the major
secreted protein of glia through LC-MS/MS analysis of
mouse mixed glial cultures. Primary mixed glial cultures
were prepared from neonatal mouse brain and treated
with LPS and IFN-γ for 24 hours. Conditioned medium
was then subjected to LC-MS/MS analysis. PAI-1 secre-
tion was strongly induced by LPS/IFN-γ treatment in
the mixed glial cultures, with the number of peptide hits
in unstimulated and LPS/IFN-γ-stimulated glia being 0
and 16, respectively.
PAI-1 secretion from mixed glial cells was verified by
western blotting analysis using a specific antibody. The
PAI-1 protein band of 47 kDa was detected in cell lysates
and conditioned medium. LPS/IFN-γ increased PAI-1 pro-
tein expression was 4.63-fold in the glial lysates and 6.23-
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Figure 2 (See legend on next page.)
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normalized to Ponceau S staining (Figure 1A). PAI-1 was
barely detectable in the conditioned medium of unstimu-
lated glial cell cultures, consistent with the LC-MS/MS
data. Soluble proteins from conditioned medium were
precipitated using TCA/acetone solution, and the precipi-
tate was solubilized in a detergent-containing buffer. This
method was used to detect the proteins of low abundance
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Figure 3 No significant effects of plasminogen activator inhibitor type 1 (PAI-1) on microglial nitric oxide (NO) production or
neurotoxicity after lipopolysaccharide (LPS) or interferon (IFN)-γ stimulation. (A) BV-2 microglial cells and (B) primary microglia cultures
were treated with the indicated concentration of mouse PAI-1 protein, LPS (100 ng/ml), and IFN-γ (50 U/ml) for 24 hours. NO production was
measured by the Griess reaction. Results are given as mean ± SD (n= 3). *P< 0.01, NS = not significant. (C) Primary microglia cultures (4.0 × 104
cells/well) were treated for 12 hours with PAI-1 (100 ng/ml), BSA (100 ng/ml), or LPS (100 ng/ml) as indicated. Afterwards, primary microglial cells
were cocultured with (upper panel) 5-chloromethyl-fluoresceindiacetate (CMFDA)-labeled primary neuron cultures for 24 hours (co-culture
scheme). (Lower panel) CMFDA-positive neurons in the five randomly chosen microscopic fields per well were counted under an inverted
microscope. Results are given as mean ± SD (n= 3). *P< 0.05, NS = not significant.
(See figure on previous page.)
Figure 2 Plasminogen activator inhibitor type 1 (PAI-1) promoted the migration of microglia in a concentration-dependent manner.
(A) BV-2 microglial cells were seeded at a density of 8.0 × 104 cells/well in 96-well plates. When the BV-2 microglial cells had reached 80 to 90%
confluence, a single scratch wound was made by using a 200 μl pipette tip, and the cell debris was removed by washing with PBS. Cells were
treated with mouse PAI-1 protein (0 to 1000 ng/ml). At 0 and 24 hours, phase-contrast pictures of the wounds at three different locations were
taken, and then the fold increase of migration distance was measured in three independent experiments. Results are given as mean ± SD (n= 3).
*P< 0.05, NS = not significant, compared with the untreated control (lower panel). Representative images are shown (upper panel; original
magnification,× 150). (B) The Boyden chamber assay was also performed to evaluate cell migration. BV-2 microglial cells (5 × 104 cells/upper well)
placed in the Boyden chambers were exposed to mouse PAI-1 protein (0 to 1000 ng/ml), and then incubated at 37°C for 6 hours. Microglial cells
that migrated through a membrane were stained and counted. Results are given as mean ± SD (n= 3). *P< 0.01; compared with the untreated
control (lower panel). Representative images are also shown (upper panel; original magnification, × 100). (C) BV-2 microglial cells were treated
with BSA (0 to 22 nmol/l) or PAI-1 (2.2 nmol/l; 100 ng/ml), followed by the wound-healing assay as described above. Results are given as mean ±
SD (n= 3). *P< 0.05, NS = not significant, compared with the untreated control. (D) BV-2 microglial cells were seeded at the density of 5.0 × 103
cells/well in 96-well plate. Cells were treated with a mouse PAI-1 protein (100 ng/ml) and incubated at 37°C for 12–72 hours to evaluate cell
proliferation. Proliferation curves are based on the 2,5-diphenyltetrazolium bromide (MTT) assay. Results represent the mean ± SD (n = 3).
Proliferation of PAI-1-treated cells (open circle) was compared with the untreated control (filled square). (E) The Boyden chamber assay was
performed to evaluate primary microglial cell migration. Primary microglia cultures (5 × 104 cells/upper well) placed in the Boyden chambers were
exposed to mouse PAI-1 protein (100 ng/ml), and then incubated at 37°C for 24 hours. Microglial cells that migrated through a membrane were
stained and counted. Results are mean ± SD (n= 3). *P< 0.05; compared with the untreated control (lower panel). Representative images are also
shown (upper panel). (F) C6 glioma cells were seeded at the density of 8.0 × 104 cells/well in 96-well plate. Cells were treated with BSA (100 ng/
ml) or PAI-1 (100 ng/ml), followed by the wound-healing assay as described above. Results are the mean ± SD (n= 3). *P< 0.05; compared with
the untreated control.
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discrepancies in the protein precipitation and solubility
may produce different protein profiles. For the direct
quantification of PAI-1 levels in the conditioned medium
and the identification of cellular source of PAI-1 secretion,
PAI-1-specific ELISA was performed for the separate glial
cell cultures. LPS/IFN-γ stimulation similarly increased
the secretion of PAI-1 in the mixed glial cells, microglia,












































































































































Figure 4 Plasminogen activator inhibitor type 1 (PAI-1) promoted microglial migration through low-density lipoprotein receptor-
related protein (LRP)1. (A, B) BV-2 microglial cells were transiently transfected with control small interfering (si)RNA or LRP1-specific siRNA. After
48 hours, a scratch wound was made. Cells were treated with or without mouse PAI-1 protein (100 ng/ml), followed by (A) the wound-healing
assay and (B) the Boyden chamber assay, as described in Figure 2. Results are given as mean ± SD (n= 3). *P< 0.05, **P< 0.01, NS = not
significant (lower panel). (Upper panels) Representative images of each assay. (C, D) Knockdown of LRP1 gene expression by siRNA was
confirmed by using (C) reverse transcriptase PCR, (D) dot blotting (upper panel), and western blotting (lower panel). β-actin and the α-tubulin
were used as internal controls. (E) BV-2 microglial cells were treated with mouse PAI-1 protein (100 ng/ml) and RAP protein (5 μg/ml) as
indicated. The fold increase in migration distance was measured using the wound-healing assay. Results are given as mean ± SD (n= 3). *P< 0.05,
NS = not significant, compared with the untreated control (lower panel). (Upper panel) Representative images also shown.
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and astrocytes contribute to glial PAI-1 secretion. PAI-1
mRNA levels were also augmented by inflammatory
stimulation in microglia and astrocytes. LPS, alone or in
combination with IFN-γ, enhanced PAI-1 mRNA expres-
sion to varying degrees in glial cell lines and cultures
(Figure 1C,D), but IFN-γ alone did not have a significant
effect. These results indicate that both microglia and astro-
cytes can be the major cellular sources of PAI-1 in the
CNS under inflammatory conditions.
Plasminogen activator inhibitor type 1 (PAI-1) promotes
microglial migration, but not microglial proliferation or
neurotoxic activation
Having shown that both microglia and astrocytes secrete
PAI-1 upon inflammatory stimulation, we next sought to
determine how glia-derived PAI-1 influences proinflam-
matory phenotypes of microglia. We focused on
microglial migration, nitric oxide (NO) production,
and neurotoxicity, because it has been suggested that
activated microglia are recruited to inflammatory sites
and produce NO and other proinflammatory mediators,
amplifying neuroinflammation and exerting neurotoxic
effects. Effects of PAI-1 on microglial cell migration were
first investigated using an in vitro wound-healing assay
(Figure 2A) and Boyden chamber assay (Figure 2B, E). The
mean plasma concentration of PAI-1 under physiological
conditions is about 6 to 80 ng/ml, but it can be increased
in a number of pathological conditions [68]. In the migra-
tion assay, we used 1 to 1000 ng/ml of recombinant mouse
PAI-1 protein, which is equivalent to 0.022 to 22.0 nmol/l.
We found that PAI-1 promoted migration of BV-2
microglial cells in a dose-dependent manner. Significant
effects on microglial migration were seen after treatment
with 10 ng/ml (0.22 nmol/l) or higher concentrations of
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Figure 5 Janus kinase (JAK)/signal transducer and activator of transcription (STAT)-1 was involved in the plasminogen activator
inhibitor type 1 (PAI-1)-enhanced microglial motility. (A) BV-2 microglial cells were treated with mouse PAI-1 protein (100 ng/ml) or
interferon (IFN)-γ (50 U/ml), and cell lysates were collected at 30 minutes after the treatment. The levels of phosphorylated STAT1 (pSTAT1 at
Tyr701) or total STAT1 protein were then evaluated by western blotting analysis. Ponceau S staining was performed to confirm the equal loading
of the samples. (B) BV-2 microglial cells were transfected with control small interfering (si)RNA or low-density lipoprotein receptor-related protein
(LRP)1 siRNA. The cells were harvested 48 hours after transfection and used for the experiments. Cells were treated with mouse PAI-1 protein
(100 ng/ml) for 30 minutes. Phosphorylated STAT1 or total STAT1 was measured by western blotting analysis. α-tubulin detection was also
performed to confirm the equal loading of the samples. Values indicate the results of densitometric quantification normalized to α-tubulin. (C)
BV-2 microglial cells were transfected with control siRNA or LRP1 siRNA. The cells were harvested at 48 hours after transfection and then treated
with mouse IFN-γ (50 U/ml) for 30 minutes. Phosphorylated STAT1 was detected by western blotting analysis. α-tubulin detection was also
performed to confirm the equal loading of the samples. (D) BV-2 microglial cells were pretreated with AG490 (JAK-specific inhibitor; 20 μmol/l)
for 30 minutes before the treatment with mouse PAI-1 protein (100 ng/ml), and then cell migration was evaluated by the wound-healing assay.
Results are mean ± SD (n= 3). *P< 0.05, NS = not significant, compared with the untreated control (lower panel). Representative images are
shown (upper panel; original magnification× 150).
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PAI-1 protein. Effects of BSA at the same molar concen-
tration (0.022 to 22.0 nmol/l) were compared as a con-
trol (Figure 2C). Sensitivity of microglia to PAI-1 was
similar to that of rat and human smooth-muscle cells,
MEF-1 fibroblasts, and HT1080 fibrosarcoma cells [35].
PAI-1 did not affect microglial proliferation (Figure 2D),
indicating that the PAI-1 promotion of wound recovery
was not related to microglial cell proliferation. PAI-1
also increased migration of primary microglia cultures
(Figure 2E). These results, taken collectively, indicate
that PAI-1 promotes the migration of microglia in cul-
ture. PAI-1 also increased C6 rat glioma cell migration
by about 1.25-fold over control (Figure 2F), suggesting
that PAI-1 may exert similar effects on the dynamics of
microglia and astrocytes. However, the effects of PAI-1
on astrocytes were not further investigated in this study.
Next, we determined whether PAI-1 could directly affect
microglial activation. Because activated microglia release
NO and other neurotoxic mediators, microglial NO pro-
duction and neurotoxicity was measured to assess micro-
glial activation. The recombinant mouse PAI-1 protein (10
to 100 ng/ml) did not affect LPS-induced NO production
(Figure 3A,B) or cell viability (data not shown) in BV-2
microglial cells or primary microglia cultures. PAI-1 did
not influence microglial neurotoxicity in microglia–neuron
cocultures (Figure 3C). LPS-stimulated microglia were
neurotoxic in the co-culture, and this was not affected by
PAI-1. These results indicate that PAI-1 does not affect
microglial activation following LPS stimulation.
Plasminogen activator inhibitor type 1 (PAI-1) promotes
microglial migration through the low-density lipoprotein
receptor-related protein 1/Janus kinase/signal transducer
and activator of transcription-1 pathway
LRP1 has been previously implicated in the biological
functions of PAI-1 [69,70]. LRP1 is a cell surface protein
that has been shown to bind to a variety of ligands in-
cluding apolipoprotein E, lipoprotein lipase, uPA, tPA,
and PAI-1 [69]. To determine the role of LRP1 in the
PAI-1-mediated microglial cell migration, we used LRP1
siRNA and RAP protein to inhibit LPR1 pathway. RAP
has been shown to bind LRP1 and block its interactions
with all known ligands including PAI-1. LRP1 gene silen-
cing using siRNA abolished the PAI-1-promoted BV-2
microglial cell migration as determined by the wound-
healing assay (Figure 4A) and the Boyden chamber assay
(Figure 4B). Knockdown of LRP1 expression was shown
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Figure 6 Plasminogen activator inhibitor type 1 (PAI-1) promoted microglial migration in vivo. (A, B) Microglial cells around the protein
injection sites were stained with anti-Iba-1 antibody at 48 hours after intrastriatal injection of vehicle (dialyzed elution buffer that was used for
PAI-1 protein purification), denatured human PAI-1 wild-type, PAI-1 wild-type, or PAI-1 R346A mutant protein (1 μl; 1.5 μg/μl). Boxes indicate the
300 × 300 μm squares placed for cell counting. Immunohistochemistry results showed that Iba-1-positive cells were recruited into the injection
site after injection of wild-type or R346 mutant PAI-1 protein. (B) Results are given as mean ± SD from three animals and six independent
sections per animal. *P< 0.05, **P< 0.01, NS = not significant. (A) Representative images (scale bar, 300 μm). Asterisks indicate the injection sites
(inj.). Guide cannula was stereotaxically located in the intrastriatal region (dotted line).
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western blotting analysis using an LRP1-specific anti-
body (Figure 4D). The addition of RAP protein alone did
not affect wound closure, but it completely blocked the
migration-enhancing effect of PAI-1 in the wound-
healing assay (Figure 4E). RAP was also able to block the
effect of PAI-1 (1–100 ng/ml) in the Boyden chamber
assay (data not shown). These results show that PAI-1
stimulates microglial migration via LRP1.
We next addressed intracellular signaling pathways
associated with the PAI-1 activity. The JAK/STAT path-
way has been previously implicated in cell migration
[71,72], and a previous study [35] has shown that PAI-1
stimulates STAT1 activation in rat smooth-muscle cells.
Thus, we evaluated the role of JAK/STAT1 pathway in
the PAI-1-promoted microglial cell migration after LRP1
binding. PAI-1 alone induced STAT1 phosphorylation as
determined by western blotting in BV-2 microglial cells
(Figure 5A). IFN-γ was used for comparison purposes [73].
LRP1 gene silencing diminished PAI-1-induced STAT1
phosphorylation (Figure 5B). LRP siRNA did not re-
duce IFN-γ-induced STAT1 phosphorylation, indicat-
ing that LRP siRNA did not cause cell toxicity
(Figure 5C). Thus, LRP1 knockdown inhibited PAI-1-
induced STAT1 expression and activation. These
results indicate that PAI-1 promotes microglial
migration through the JAK/STAT1 pathway, and that
LRP1 may reside in the upstream of the JAK/STAT1
signaling pathway in microglia. Indeed, the addition
of AG490, a pharmacological inhibitor of JAK kinase,
significantly attenuated the PAI-1-induced BV-2
microglial cell migration in the wound-healing assay
(Figure 5D). These data indicate that PAI-1 enhances
microglial cell migration via LRP1 and the JAK/
STAT1 pathway.
Plasminogen activator inhibitor type 1 (PAI-1) is an
inducer of microglial migration in vivo
To determine whether PAI-1 promotes microglial motil-
ity in vivo, microglial accumulation was investigated
after intrastriatal injection of human PAI-1 protein. Ve-
hicle, denatured wild-type human PAI-1, wild-type
human PAI-1, or the R346A human PAI-1 protein mu-
tant were stereotaxically injected into the striatum of the
mouse brain. Accumulation of microglia was immuno-
histochemically evaluated by counting Iba-1-positive
cells around the injected area. At 48 hours after intras-
triatal injection of wild-type human PAI-1 protein, there
were large numbers of Iba-1-positive microglia accumu-
lated around the PAI-1 injection site (Figure 6A,B). The





































Figure 7 Plasminogen activator inhibitor type 1 (PAI-1)-induced microglial migration was independent of fibrinolysis or vitronectin
binding. BV-2 microglial cells were treated with 100 ng/ml of mouse PAI-1, human wild-type PAI-1, or two variants (Q123K, R346A) of PAI-1
proteins, followed by a wound-healing assay as described in Figure 2. The wound recovery areas were visualized under an inverted microscope
(upper panel), and the fold increase in migration distance was measured. Results are given as mean ± SD (n= 3). *P< 0.05, **P< 0.01; compared
with the untreated control (lower panel).
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inhibiting PA, similarly induced microglial accumulation
around the injection site. Denatured PAI-1 protein had
no effect. Because the injection alone may cause tissue
injuries, a basal level of microglial accumulation was
seen after vehicle injection. Because PAI-1 did not in-
duce microglial activation in vitro (Figure 3A,B), we sug-
gest that the microglial accumulation seen in this
experiment probably results from microglial recruitment
rather than activation. The microglial migration-promoting
activity of the R346A mutant protein was also seen in an
in vitro migration assay, indicating that the PAI-1 effects
are independent of the fibrinolysis system (Figure 7).
Additionally, the Q123K mutant of human PAI-1
retained the migration-promoting activity in vitro,
thereby suggesting that binding of PAI-1 to
vitronectin may not be required for the activity. Re-
combinant human PAI-1 protein has been shown pre-
viously to be effective in mice [74]. Indeed, human
and mouse PAI-1 protein exerted similar effects on
the stimulation of microglial migration (Figure 7). To
further exclude the possibility that microglial accu-
mulation around the injection site is not due to cell
activation or proliferation, another in vivo migration
assay was performed using a stab-injury/cell-injection
model, which has been previously used to determine
glial cell migration in vivo [57,58]. In this method, fluores-
cently labeled microglial cells were injected into the cortex,
and their migration toward the stab-injury site monitored.
For this, primary microglial cells were treated with 1 μg/ml
























































Figure 8 Plasminogen activator inhibitor type 1 (PAI-1) enhanced 5-chloromethyl-fluoresceindiacetate (CMFDA)-labeled microglial
migration in vivo. The effect of PAI-1 on microglial migration was examined using a stab-injury/cell-injection model. Primary microglia were
treated with 1 μg/ml of PAI-1 protein (denatured wild-type protein (control), wild-type protein, R346A mutant protein) for 12 hours. Microglial
cells were then labeled with CMFDA and injected into the mouse brain. (A) After 72 hours, three areas (cell-injection site (area 1), an intermediate
location between the injection site and the stab-injury site (area 2), and the stab-injury site (area 3) were chosen for the analysis of CMFDA-
labeled microglial cell migration (left panel). (A) A schematic diagram of the stab-injury/cell-injection model is also shown (right panel). The stab
injury (3 mm long, 2 mm deep) was created 2 mm posterior to the bregma and 4 mm right lateral to the midline. (B) Representative images of
CMFDA (green) and Iba-1 (red) staining. Scale bar, 20 μm. (C) Iba-1 microglial staining in the three areas of brain. Scale bar, 200 μm.
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wild-type protein, R346A mutant protein) for 12 hours, and
the cells labeled with CMFDA. The CMFDA-labeled
microglial cells were injected into the mouse brain, and
then the stab injury was created. After 72 hours, three dif-
ferent areas (the cell-injection site, a location inter-
mediate between the injection site and the stab-injury
site, and the stab-injury site) were visible (Figure 8).
Iba-1 immunostaining was also performed to identify
microglial cells. Iba-1/CMFDA double-labeled cells
were accumulated around the stab-injury site in the
mouse brains after injection with PAI-1 wild-type or
R346A mutant protein-treated microglia. Denatured
PAI-1 protein had no effect. The results support the
notion that PAI-1 promotes microglial migration
in vivo.
Plasminogen activator inhibitor type 1 (PAI-1) derived
from astrocytes regulated microglial migration
In a series of experiments, we presented evidence that
addition of exogenous PAI-1 protein promotes micro-
glial migration both in vitro and in vivo. We next aimed
to determine the role of endogenous PAI-1 protein in
the regulation of microglial migration. Although micro-
glia may contribute to PAI-1 secretion, astrocytes are
thought to be the major cellular source of PAI-1 in the
CNS in vivo [23,43,75,76], because astrocytes outnumber
microglia in the brain. Astroglial PAI-1 release was also
detected in the current study (Figure 1B). Thus, we
assessed the role of astrocyte-derived PAI-1 in the regu-
lation of microglial migration using ACM and neutraliz-
ing antibodies against PAI-1. ACM was prepared from
primary astrocyte cultures stimulated with a combin-
ation of LPS and IFN-γ. ACM promoted the migration
of BV-2 microglial cells as determined by the wound-
healing assay (Figure 9). To neutralize the PAI-1 activity in
the ACM, a polyclonal anti-PAI-1 antibody was applied to
BV-2 microglial cells together with ACM. Normal rabbit
serum was used as a control. Abolishment of PAI-1 activity
using anti- PAI-1 antibody significantly inhibited the effect
of LPS/IFN-γ-stimulated ACM on microglial migration
(Figure 9). PAI-1 neutralization also attenuated the effect of
unstimulated ACM, indicating the presence of a low
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Figure 9 Astrocyte-derived plasminogen activator inhibitor type 1 (PAI-1) promoted the migration of microglia. Primary astrocytes were
left untreated or treated with lipopolysaccharide (LPS; 100 ng/ml) and interferon (IFN)-γ (50 U/ml) for 12 hours. Cells were then washed twice
with PBS, and cultured in fresh DMEM for an additional 24 hours. The astrocyte-conditioned medium (ACM) was then collected. BV-2 microglial
cells were treated for 24 hours with ACM in the presence or absence of PAI-1 neutralizing antibody (PAI-1 Ab; 2 μg/ml), or normal rabbit serum
(2 μg/ml) as control. Microglial migration was assessed by wound-healing assay as described in Figure 2. At 0 and 24 hours, phase-contrast
images of the wounds at three different locations were taken (upper panel, original magnification, × 150), and then fold increase in migration
distance from three independent experiments was measured (lower panel). Results are given as mean ± SD (n= 3). *P< 0.05, **P< 0.01, NS = not
significant.
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concentration of PAI-1 in the control ACM. These results
further support that PAI-1 plays an important role in neu-
roinflammation by promoting microglial migration.
Plasminogen activator inhibitor type 1 inhibited
microglial phagocytosis of zymosan particles
The effect of PAI-1 protein on the phagocytic activity
of microglia was next investigated using zymosan par-
ticles as a prey. Zymosan particles are components of
yeast cell wall, and served as a model for the phago-
cytosis of invading microbes [77]. The recombinant
mouse PAI-1 protein inhibited the engulfment of
zymosan particles in both BV-2 microglial cells and
primary microglia cultures (Figure 10A, C). PAI-1
inhibited the microglial phagocytic activity in a dose-
dependent manner, as 1000 ng/ml of PAI-1 treatment
produced greater inhibition than 100 ng/ml
(Figure 10A). BSA (2.2 or 22.0 mol/l) did not inhibit
the phagocytic activity of microglia (Figure 10B). To
identify the role of LRP1 in the PAI-1 inhibition of
microglial phagocytosis, primary microglial cultures
were treated with PAI-1 in the presence of RAP pep-
tide (Figure 10C). The addition of RAP did not affect
the PAI-1 inhibition of microglial phagocytic activity,
indicating that LRP1 is not involved in the PAI-1 re-
duction of microglial phagocytosis. TLR2, TLR6 and
glucan receptor dectin-1 have been previously impli-
cated in the recognition and phagocytosis of zymosan
particles in either a cooperative or independent man-
ner [78,79]. The mRNA (Figure 11A) and protein
(Figure 11B) levels of TLR2 and TLR6 were markedly
decreased after 6 hours of PAI-1 treatment, but there
was no significant difference in dectin-1 mRNA or
TLR9 protein levels (Figure 11A, B). Consistent with
TLR2 mRNA/protein reduction, PAI-1 inhibited
TLR2-mediated microglial activation as determined by
NO production after stimulation with the TLR2 agon-































































Figure 10 Plasminogen activator inhibitor type 1 (PAI-1) inhibited microglial phagocytosis of zymosan particles. (A) BV-2 microglial cells
were treated with PAI-1 (100 or 1000 ng/ml) for 1 hour and then incubated with zymosan particles conjugated with Alexa Fluor 594 (red) for 3
hours. Cells were washed five times with ice-cold PBS to remove bound particles. (A) Images at five different locations were taken and then the
percentage of phagocytic cells was calculated based on the number of microglial cells that phagocytosed the zymosan particles (lower panel).
(Upper panel) Representative images are shown. Results are given as mean ± SD from three independent experiments. *P< 0.05, **P< 0.01,
different from untreated control. Scale bar = 20 μm. (B) BV-2 microglial cells were treated with BSA (2.2 or 22 nmol/l) or PAI-1 (2.2 nmol/l; 100 ng/
ml) for 1 hour and then incubated with zymosan particles for 3 hours, followed by the phagocytosis assay as described above. Results are given
as mean ± SD from three independent experiments. *P< 0.05, NS = not significant, compared with the untreated control. Scale bar = 20 μm. (C)
Primary microglia were treated with BSA (100 ng/ml), PAI-1 (100 ng/ml), or RAP protein (5 μg/ml) for 1 hour and then incubated with zymosan
particles for 90 minutes. Microglial phagocytosis was assessed as described above. Results are given as mean ± SD (n= 3). *P< 0.05, NS = not
significant.
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To further define the inhibitory mechanism of PAI-1
in microglial phagocytosis, we used wild-type human
PAI-1 protein, and the R346A and Q123K mutants of
this protein. The wild-type protein and the R346A
mutant (unable to inhibit PA) inhibited the engulf-
ment of zymosan particles, whereas the Q123K mu-
tant (with impaired vitronectin binding activity) did
not have an inhibitory effect (Figure 12A). The
addition of recombinant vitronectin protein to PAI-1-
treated microglial cells rescued the phagocytic activity
(Figure 12B). We speculate that PAI-1 may inhibit the
engulfment of zymosan particles by interfering with
vitronectin/ITGB3 interaction. Vitronectin is a multi-
functional molecule that binds to PAI-1, ITGB3, and
bacteria [80]. To verify our hypothesis, the anti-TLR2
or anti-ITGB3 antibodies were applied to BV-2 micro-
glial cells together with zymosan particles. Neutralization of
either TLR2 or ITGB3 significantly inhibited microglial
phagocytosis. The percentage inhibition by anti-TLR2
or anti-ITGB3 antibody was similar to that of recom-
binant PAI-1 (Figure 12C). These results suggest that
PAI-1 may inhibit microglial phagocytic activity via
TLR2 and ITGB3.
Discussion
Stimulated glial cells release various proinflammatory pro-
teins such as cytokines, chemokines, and neurotoxic fac-
tors under pathological conditions [1,2]. These soluble
proteins may play important roles in the progression of in-
flammatory diseases. Secretomic analysis of glia has been
previously used to determine the secreted protein profiles
during inflammatory responses [3,4,6,51,65,66,81]. In this
study, we found that PAI-1 is one of the major proteins
released by mixed glial cultures after inflammatory stimu-
lation, and we provide evidence that PAI-1 is able to regu-
late microglial activation, migration, and phagocytosis
under inflammatory condition.
PAI-1 is the primary inhibitor of uPA and tPA, which
are involved in fibrinolysis [21,82]. PAI-1 also exerts nu-
merous effects that are not dependent on PA inhibition
[27,28,83]. PAI-1 levels are increased in brain diseases
such as glioma, hypoxia, ischemic stroke, MS, and AD
[38-41]. Astrocytes, but not microglia, are thought to be
the major cellular source of PAI-1 in the CNS in vivo
[23,43,75,76]. Our data suggest that microglia can also
be a source of PAI-1 in the CNS. A recent study indi-




















































Figure 11 Plasminogen activator inhibitor type 1 (PAI-1) downregulated Toll-like receptor (TLR)2/6 expression and its signaling.
(A) BV-2 microglial cells were treated with PAI-1 (100 ng/ml) for 5 hours. TLR2/TLR6 and dectin-1 gene expression was detected by reverse
transcriptase PCR. β-actin was used as an internal control. (B) Alternatively, BV-2 microglial cells were treated with PAI-1 (100 ng/ml) for 24 hours.
The levels of TLR2, TLR6, and TLR9 protein were then evaluated by western blotting analysis. α-tubulin was used as an internal control. Values
indicate the results of densitometric analysis normalized to either β-actin or α-tubulin. (C) Primary microglia cultures were treated with mouse
PAI-1 protein (100 ng/ml), lipopolysaccharide (LPS; 100 ng/ml), interferon (IFN)-γ; 50 U/ml), and lipoteichoic acid (LTA; 1 μg/ml) as indicated for 24
hours. (Upper panel) NO production was measured by a Griess reaction. (Lower panel) Cell viability was measured by 2,5-diphenyltetrazolium
bromide (MTT) reduction assays, and the results expressed as the percentage of surviving cells over the control cells . Results are given as mean ±
SD (n= 3). *P< 0.01, NS = not significant.
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ensheathing glia [44]. In the current study, PAI-1 mRNA
expression was detected in primary astrocytes, primary
microglia cultures, and cell lines of microglia or astro-
cyte origin (Figure 1C,D). PAI-1 protein secretion was
increased in the LPS/IFN-γ-stimulated primary microglia
and astrocyte cultures (Figure 1B). Thus, PAI-1 secreted by
microglia or astrocytes may regulate microglial motility and
phagocytic activity in an autocrine or paracrine manner
under inflammatory conditions. Because microglial activa-
tion and ensuing neuroinflammation are key components
of neurodegenerative diseases such as AD, PD, and MS,
PAI-1 is likely to play an important role in regulating the
inflammatory activation of microglia. Microglia-mediated
neuroinflammation is characterized by a series of events,
with a crucial step being the migration of microglia to the
site of brain injury or inflammation [2,84], of which PAI-1
seems to be a central regulator. We found that PAI-1
modulates microglial activation after stimulation with
TLR2 (Figure 11C), but not TLR4 (Figure 3A,B). TLR2 has
been previously shown to exacerbate ischemic brain dam-
age [85]. PAI-1 may play a regulatory role under
pathological condition by suppressing TLR2 signaling. In-
deed, PAI-1 has been shown to prevent apoptosis and even
to protect against brain injury [42].
PAI-1 has been previously implicated in cell migration [86],
and regulates cell migration through multiple mechanisms.
PAI-1 has been shown to either enhance or suppress cell
migration by interacting with various partner proteins
such as uPA, tPA, LRP1, and vitronectin. PAI-1 suppresses
cell migration by binding to vitronectin or uPA/uPAR.
PAI-1 inhibited the motility of vascular smooth-muscle
cells, human amnion WISH cells, and carcinoma cells via
interaction with vitronectin [28-30,87], and vitronectin
blocked the LRP1/PAI-1 pathway [33]. The PAI-1/uPA/
uPAR complex inhibited uPA-induced cell migration [34],
whereas this complex mediated vitronectin-induced cell
migration [88]. PAI-1 has been implicated in cancer inva-
sion [89,90] and angiogenesis [90]. PAI-1 stimulated the
migration of monocytes and macrophages by interact-
ing with LRP or tPA. By binding to LRP1, PAI-1 also
enhanced the migration of rat and human smooth-
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Figure 12 Plasminogen activator inhibitor type 1 (PAI-1) inhibited microglial phagocytosis in a vitronectin-dependent manner. (A) BV-2
microglial cells were treated with 100 ng/ml of human wild-type PAI-1, the Q123K variant, or the R346A variant for 1 hour, and then incubated
for 3 hours with zymosan particles. (A) Microglial phagocytosis of fluorescent zymosan particles was assessed (lower panel) as described above.
(Upper panel) Representative images are shown. Results are given as mean ± SD (n= 3). *P< 0.05, NS = not significantly different from untreated
control. Scale bar = 20 μm. (B) BV-2 microglial cells were treated with human wild-type PAI-1 or the Q123K mutant (100 ng/ml) in the presence or
absence of vitronectin (1 μg/ml) for 1 hour, and then incubated with zymosan particles for 3 hours, followed by phagocytosis assay. Results are
given as mean ± SD (n= 3). *P< 0.05, NS = not significant. (C) BV-2 microglial cells were incubated with zymosan particles in the presence or
absence of Toll-like receptor (TLR)2 antibody (TLR2 Ab; 2 μg/ml), integrin (ITG)B3 antibody (ITGB3 Ab; 2 μg/ml), normal rabbit serum (2 μg/ml;
negative control), or PAI-1 (100 ng/m; positive control). Microglial phagocytosis assay was performed. Results are given as mean ± SD (n= 3).
*P< 0.05, **P< 0.01, compared with normal serum.
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fibrosarcoma cells (HT1080) [35]. PAI-1 also pro-
moted the migration of lymphocytes and neutrophils
into inflammatory sites [35,91,92]. Deficiency of PAI-1
abolished the migration of exudate macrophages [93].
The LRP/tPA/PAI-1 complex coordinated Mac-1-
dependent macrophage migration [37]. In the previous
studies, the regulatory effects of PAI-1 on cell migration
have been shown in various cell types such as monocytes
and endothelial cells. However, it is not clear whether
PAI-1 has positive or negative effects on glial cell migra-
tion in the CNS. The composition of the extracellular
matrix (ECM) in the CNS is different from that of other
tissue types. Laminin, fibronectin, and collagen are the
major components of the ECM in most tissues, but are
largely undetectable in the CNS [94-96]. Because the ef-
fect of PAI-1 heavily depends on ECM components such
as vitronectin, PAI-1 may not necessarily play the same
role in the CNS as in other peripheral tissues. In this
study, we found that PAI-1 exerts positive effects on cell
migration in the CNS. PAI-1 stimulated microglial migra-
tion through the LRP-1/JAK/STAT axis (Figure 4; Fig-
ure 5), which is consistent with previous reports in which
STAT1 activation was found to be involved in PAI-1
induced cell migration in rat and human smooth-muscle
cells and fibroblasts [35]. We used two different PAI-
1 mutants to further characterize the cell migration-
promoting activity of PAI-1. Vitronectin, in addition
to PA, has been identified as a PAI-1-binding protein.
The Q123K and R346A mutants, which, respectively,
are unable to bind to vitronectin and unable to in-
hibit PA, retained the microglial migration-promoting
activity (Figure 6, Figure 7, Figure 8). These results
suggest that the microglia migration-regulating activ-
ity of PAI-1 we observed in the current study may
not depend on either vitronectin binding or PA
inhibition.
Recent reports indicated a novel role of PAI-1 in the
regulation of phagocytosis of apoptotic or viable cells
[27,97]. Our results show that PAI-1 inhibits microglial
phagocytosis of zymosan particles (Figure 10 A,C).
Human PAI-1 proteins (both wild-type and the R346A
mutant) inhibited microglial phagocytic activity, whereas
the Q123K mutant (unable to bind to vitronectin) did
not. These results prompted us to speculate that PAI-1
inhibits microglial phagocytosis by binding to vitronec-
tin, which is a functional partner of PAI-1. The PAI-1
/vitronectin complex interacts with the Arg-Gly-Asp
motif of ITGB3, inhibits fibrinolysis, and modulates the
pro-migratory effect of PAI-1 [28,30,32,33,87]. Vitronec-
tin and integrin were previously shown to be required
for TLR2-mediated activation of monocytes [98], and
zymosan phagocytosis was dependent on TLR2 and
TLR6 [99-101], while TLR2 deficiency attenuated bacter-
ial clearance [102]. Our results suggest that PAI inhibits
microglial phagocytosis by blocking the vitronectin/
ITGB3/TLR2 complex. Indeed, neutralization of ITGB3
or TLR2 inhibited microglial phagocytosis (Figure 12C).
We also found that PAI-1 inhibited TLR2 and TLR6 ex-
pression (Figure 11A,B). Thus, PAI-1-mediated downre-
gulation of TLR2 seems to reduce microglial phagocytic
activity.
Conclusions
In this study, we found that PAI-1 released from micro-
glia and astrocytes promotes microglial migration and
inhibits phagocytosis in vitro. Some of our in vitro find-
ings were supported by animal studies, in which PAI-1
was found to stimulate microglial recruitment into the
injury site in mouse brain. PAI-1 promoted microglial mi-
gration via the LRP1/JAK/STAT1 axis, and inhibited
microglial phagocytosis of zymosan particles. Extensive
studies have been conducted for PAI-1 in cardiovascular
diseases, obesity, and diabetes [103-107], but little is
known about its role in inflammatory diseases of the brain.
Our results suggest PAI-1 as a potential therapeutic target
to control microglial migration and phagocytosis under
pathological conditions in the CNS.
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